As a group of immature myeloid cells capable of suppressing immune responses, MDSCs inhibit the immune response mainly by acting on the tumor immune environment (including activation of M2-TAM and Treg cells and suppression of CD8+ T-cells and NK cells), blocking lymphocyte homing, and promoting epithelial–mesenchymal transition (EMT) and angiogenesis [100–105]. The gene discussed is CD8A; the disease is neoplasm.